Please enable Javascript
2021 ASH Annual Meeting: Focus on GVHD for Pharmacists
Better Access to Transfusion Services Could Improve Hospice Enrollment
DocWire News Editors
ASH Annual Meeting and Exposition 2021
|
April 24, 2023
Patients with hematologic malignancies who may require blood transfusions may not be able to enroll in hospice care ...
Analysis Identifies Factors Prognostic of Ruxolitinib Failure in Chronic GVHD
DocWire News Editors
ASH Annual Meeting and Exposition 2021
|
April 24, 2023
Updated results from a real-world analysis confirm that ruxolitinib is an effective treatment option for patients with ...
Fitusiran Reduces Bleeding Risk in Patients With Hemophilia A or B Without Inhibitors
DocWire News Editors
ASH Annual Meeting and Exposition 2021
|
August 25, 2023
Prophylactic treatment with subcutaneous fitusiran administered once-monthly reduced bleeding risk in patients with ...
Post-Transplant Cyclophosphamide and Tacrolimus Effectively Prevents GVHD in Older Adults Undergoing AlloHCT
DocWire News Editors
ASH Annual Meeting and Exposition 2021
|
April 24, 2023
According to a poster presented at the 2021 ASH Annual Meeting by Maria Queralt Salas, MD, from the Hospital Clinic of ...
Dara-KRd Quadruplet Plus AHCT and Consolidation Leads to High MRD Negativity
DocWire News Editors
ASH Annual Meeting and Exposition 2021
|
July 5, 2023
The combination of daratumumab, carfilzomib, lenalidomide, and dexamethasone (Dara-KRd), autologous hematopoietic cell ...
Oncology APPs Face Constraints on Prescribing Chemotherapy
DocWire News Editors
ASH Annual Meeting and Exposition 2021
|
April 24, 2023
Prescribing chemotherapy is not a universal practice of advanced practice providers (APPs) in the oncology community, ...
Advertisement
Advertisement
Advertisement
Advertisement